Cullinan Oncology Llc Stock Today
| CGEM Stock | USD 12.22 0.36 2.86% |
Performance0 of 100
| Odds Of DistressLess than 47
|
Cullinan Oncology is selling at 12.22 as of the 21st of November 2024; that is 2.86 percent decrease since the beginning of the trading day. The stock's lowest day price was 12.04. Cullinan Oncology has 47 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Cullinan Oncology LLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of January 2021 | Category Healthcare | Classification Health Care |
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. The company has 58.23 M outstanding shares of which 9.02 M shares are currently shorted by private and institutional investors with about 24.87 trading days to cover. More on Cullinan Oncology LLC
Moving together with Cullinan Stock
| 0.65 | VRAX | Virax Biolabs Group | PairCorr |
| 0.64 | DYN | Dyne Therapeutics | PairCorr |
| 0.82 | XFOR | X4 Pharmaceuticals | PairCorr |
Moving against Cullinan Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cullinan Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Nadim Ahmed | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCullinan Oncology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cullinan Oncology's financial leverage. It provides some insight into what part of Cullinan Oncology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cullinan Oncology LLC (CGEM) is traded on NASDAQ Exchange in USA. It is located in One Main Street, Cambridge, MA, United States, 02142 and employs 85 people. Cullinan Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 732.5 M. Cullinan Oncology LLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 58.23 M outstanding shares of which 9.02 M shares are currently shorted by private and institutional investors with about 24.87 trading days to cover.
Cullinan Oncology LLC currently holds about 611 M in cash with (134.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cullinan Oncology Probability Of Bankruptcy
Ownership AllocationThe majority of Cullinan Oncology LLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cullinan Oncology LLC to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cullinan Oncology. Please pay attention to any change in the institutional holdings of Cullinan Oncology LLC as this could imply that something significant has changed or is about to change at the company.
Check Cullinan Ownership Details
Cullinan Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Alliancebernstein L.p. | 2024-06-30 | 1.7 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.7 M | |
| Avidity Partners Management Lp | 2024-06-30 | 1.6 M | |
| Vr Adviser, Llc | 2024-06-30 | 1.4 M | |
| Holocene Advisors, Lp | 2024-06-30 | 1.3 M | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | |
| Braidwell Lp | 2024-09-30 | 1.2 M | |
| Orbimed Advisors, Llc | 2024-06-30 | 1.1 M | |
| Nextech Invest Ag | 2024-09-30 | 1.1 M | |
| Mpm Oncology Impact Management Lp | 2024-09-30 | 7.6 M | |
| Bvf Inc | 2024-09-30 | 5.8 M |
Cullinan Oncology Historical Income Statement
Cullinan Stock Against Markets
Cullinan Oncology Corporate Management
| Jennifer Michaelson | Chief Officer | Profile | |
| Kerry Whalen | Director Devel | Profile | |
| Jeffrey Trigilio | CFO Treasurer | Profile | |
| Mary Fenton | Chief Officer | Profile | |
| Jacquelyn JD | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.